Medical Devices Latin America

Latin America Neuromodulation for Depression Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Latin America Neuromodulation for Depression Market Industry Trends and Forecast to 2034: Segmented by (Technology, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Latin America · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $66.0 Mn Placeholder estimate
Estimate 2025 $73.3 Mn 4.7% of the global market
Projected 2034 $189.1 Mn 157.9% Adds $115.8 Mn over 9 forecast years
CAGR 2025–2034 11.1% Faster than 63% of 186 Medical Devices markets here
Key players 5
  • Latin America is 4.66% of the global market.
  • Among regions, the largest is North America at $807.4 Mn.
  • Fastest growing: Africa at 11.4% a year.
  • Latin America ranks 4th of 6 by size among regions.

Market size projection

Latin America

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$115.8 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Neuromodulation for Depression Market market size by year, Latin America
YearMarket sizeChange that yearSince 2025
2024 (estimate) $66.0 Mn — —
2025 (base) $73.3 Mn +$7.3 Mn —
2026 (forecast) $81.5 Mn +$8.1 Mn +11.1%
2027 (forecast) $90.5 Mn +$9.0 Mn +23.4%
2028 (forecast) $100.5 Mn +$10.0 Mn +37.1%
2029 (forecast) $111.7 Mn +$11.2 Mn +52.4%
2030 (forecast) $124.1 Mn +$12.4 Mn +69.3%
2031 (forecast) $137.9 Mn +$13.8 Mn +88.1%
2032 (forecast) $153.2 Mn +$15.3 Mn +108.9%
2033 (forecast) $170.2 Mn +$17.0 Mn +132.1%
2034 (forecast) $189.1 Mn +$18.9 Mn +157.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Latin America Neuromodulation for Depression Market Analysis at a glance
Market size, 2025$73.3 Mn placeholder estimate
Forecast, 2034$189.1 Mn placeholder estimate
Growth (CAGR), 2025–203411.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTechnology, setting and end user (see all)
Key playersNeuronetics, BrainsWay, Magstim, LivaNova PLC, Flow Neuroscience (see all)
Active clinical trials9 in Latin AmericaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Latin America. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Latin America Neuromodulation for Depression Market Analysis Executive Summary

Neuromodulation for depression uses magnetic or electrical stimulation of the brain, such as TMS, to treat depression that does not respond to medicines.

Key segments of the neuromodulation for Depression market include technology (Transcranial Magnetic Stimulation, Electroconvulsive Therapy and Vagus Nerve Stimulation) and setting (Clinics, Hospitals and Home).

Bar chart: Latin America Neuromodulation for Depression market size, 2024–2034, placeholder estimates. $66.0 Mn in 2024, $73.3 Mn in 2025 and $189.1 Mn in 2034, 11.1% CAGR.
Latin America Neuromodulation for Depression market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Latin America Neuromodulation for Depression Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the neuromodulation for Depression market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the neuromodulation for Depression market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the neuromodulation for Depression market.

Competitive Landscape for Neuromodulation for Depression Market in Latin America

The neuromodulation for Depression market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Neuromodulation for Depression Market in Latin America

Neuromodulation for Depression in Latin America: rules, payment and research

In some of the countries we cover here, medical devices are regulated by ANVISA (Brazil)⁠[1], ARCSA (Ecuador)⁠[2], COFEPRIS (Mexico)⁠[3], ANMAT (Argentina)⁠[4], INVIMA (Colombia)⁠[5] and ISP (Chile)⁠[6]. How care is paid for in some of these countries: the SUS (Brazil)⁠[7]; public care and IESS (Ecuador)⁠[8]; IMSS, ISSSTE and IMSS-Bienestar (Mexico)⁠[9]; public care, obras sociales and prepaid plans (Argentina)⁠[10]; social health insurance (EPS) (Colombia)⁠[11]; and FONASA and ISAPREs (Chile)⁠[12]. ClinicalTrials.gov lists 9 studies on Neuromodulation for Depression that are recruiting, active or about to start in Latin America.⁠[13]

[1] ANVISA. Checked 14 Nov 2026.

[2] ARCSA. Checked 14 Nov 2026.

[3] COFEPRIS. Checked 14 Nov 2026.

[4] ANMAT. Checked 19 Nov 2026.

[5] INVIMA. Checked 19 Nov 2026.

[6] Institute of Public Health of Chile (ISP). Checked 19 Nov 2026.

[7] CONITEC. Checked 14 Nov 2026.

[8] Ministry of Public Health of Ecuador. Checked 14 Nov 2026.

[9] Mexican Social Security Institute (IMSS). Checked 14 Nov 2026.

[10] Superintendence of Health Services (SSSalud). Checked 19 Nov 2026.

[11] Ministry of Health and Social Protection. Checked 19 Nov 2026.

[12] FONASA. Checked 19 Nov 2026.

[13] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Latin America. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how neuromodulation for Depression products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Latin America.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Neuromodulation for Depression right now, from free public sources.

Clinical trials

9 active trials in Brazil, Mexico, Argentina, Colombia, Chile, Ecuador and Haiti

Recruiting, about to start, or running now. Counted across the 7 countries we report on in Latin America.

Top trial sponsors (worldwide)

  1. Magnetic Tides 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 21 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Neuromodulation for Depression in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Neuromodulation for Depression market in Latin America?
Placeholder estimate: about $73.3 Mn in 2025, rising to about $189.1 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Neuromodulation for Depression market in Latin America growing?
Placeholder estimate: about 11.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Neuromodulation for Depression market report cover?
The report splits the market by technology (Transcranial Magnetic Stimulation, Electroconvulsive Therapy, Vagus Nerve Stimulation, tDCS), setting (Clinics, Hospitals, Home) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Neuromodulation for Depression market?
Key players include Neuronetics, BrainsWay, Magstim, LivaNova PLC and Flow Neuroscience.
What is driving the Neuromodulation for Depression market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the neuromodulation for Depression market. Governments and employers are investing more in mental health care.
How many clinical trials on Neuromodulation for Depression are running in Latin America?
9 studies are recruiting, active or about to start in Latin America, counted across the 7 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Latin America. Retrieved 12 Nov 2026.
How much research is published on Neuromodulation for Depression?
PubMed lists 74 papers on Neuromodulation for Depression added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Latin America

See all

Related on mental health and brain and nerves

See the topic